For example, in a recent study, Tazemetostat (an EZH2 chemical inhibitor which is used in many clinical trials) is more effective to target B-cell lymphoma cell lines models bearing EZH2 activating mutations than models bearing wild-type EZH2 since cell viability is less dependent on EZH2 in WT cells. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.